Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market is Expected to Reach $24 bn by 2026
The Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market was valued at around US$15 billion at the end of 2018. The revenue is said to engross over US$24 billion by 2026, with a CAGR of 6.1%.
ADHD, classified under the diagnostic criteria DSM-5 by the American Psychiatric Association (APA), characterized by patterns of hyperactivity, inattentions, and impulsivity. The worldwide prevalence of ADHD in children was around 2.3% and 2.8% among adults, in 2018. The reported cases of ADHD in the US alone was around 8.1% in children and 5.2% among adults, in 2017, followed by the European Union nations. With around 68 therapeutic options in active development, product launches and more investment in research and development is set to contribute to the market growth through the forecast period 2019-2026.
Continuous rise in the adult ADHD population with many yet to be diagnosed and the policies drafted at the national level are set to drive the market a CAGR of 6.1% throughout the forecast period. For example, the US government conducts national-level surveys assess ADHD population with the help of the Centre for Diseases Control (CDC) which also assesses the ADHD treatment medications covered by state-sponsored insurance or through Medicaid. In 2016, The US government allocated funds of more than US$50 million to address the treatment requirements of individuals with psychological disorders. Similarly, the National Health Services (NHS), UK allocated US$1.2 billion owing to set-up a five-year plan for aiding patients suffering from mental illnesses.
During recent times, increasing awareness of mental illness is on the rise among the global population with more focus on infants and adolescent population. Parents are ready to go the extra mile to groom their children and provide comfort to raise their children without any psychological problems. This is set to boost the market growth during the forecast period from 2019 to 2026.
However, lack of accurate biomarkers for diagnosing ADHD and unknown genetic causes are still grey areas which have to be addressed. Due to this, the cost of diagnosis is also on the higher side. Besides, the cost of treatment is also likely to hamper the market growth. With more investment contribution towards R&D for developing towards improved and accurate diagnostic methodologies should drive the market during the upcoming years.
The ADHD Treatment Market Outlook 2019-2026, from Optima Insights, will offer a thorough insight on the market growth till the forecast year 2026 based on the market segmentation (Drug Class, Age, Distribution Channel, and Region). The report comprises comprehensive profiling of companies involved in drug development, products of ADHD and pipeline information (inclusive of clinical trial data).
The drug class which is used for ADHD can be classified as Stimulants and Non-stimulants. Stimulants include Lisdexamfetamine dimesylate, Dexmethylphenidate, Dextroamphetamine, Methylphenidate, and Amphetamine. While the non-stimulant types are Clonidine, Bupropion, Atomoxetine, and Guanfacine.
Stimulant drugs dominated the market share in the year 2018. The stimulant drugs always have an upper hand over the non-stimulant drugs attributing to more efficacy. For example, Shire’s Lisdexamfetamine ruled the ADHD drug sales in the year 2013 and had also demonstrated to be a gold standard comparable to the other drug lines. Owing to its efficacy, the prescription of stimulant drugs for treating ADHD is increasing. In the year 2018 alone, the usage of the stimulant drug among young ADHD patients was more than 1.56 million, while the adult ADHD individuals taking stimulant drugs were more than 4 million. Recently, the FDA approved Adhansia XR, a high dose (60mg) drug of Purdue Pharma for treating ADHD in children of around 6 years. With more clinical trials underway and govt. support for the usage of stimulant drugs is driving the stimulant ADHD drug market.
However, the lack of evidence on long-term usage of stimulant drugs for ADHD treatment is still debatable. Whereas, non-stimulants are growing in popularity among the US & European populace due to its long-lasting effect and considerably low-risk element. Also, the investments to boost the non-stimulant drug therapies are increasing which is said to drive the drug market in equivalence to the stimulant drug therapies.
The awareness of ADHD is accompanying with frequent clinical visits and physician consults increasing prescription drugs where retails pharmaceutical outlets play a pivotal role and is driving the segment over hospitals segment. This is due to the fact, that hospital inpatient is less owing to lengthy treatment regimens. Thus, making the patients rely on the pharmacies.
Especially, in the US, the amount of prescriptions is more and is increasing every year. Also, the number of ADHD patients in the US are high in number contributing to the North American regional market growth. The North American region is also experiencing the rise of new market entrants because of more investment in R&D and focus on developing therapies that could contribute to improving the lifestyle of the ADHD patient. Following North America, European Market is also said to contribute to the market share. Both North America and US medical coverage policies also contribute to the market share when compared to the other regions such as APAC and LAMEA, which are considered emerging markets with awareness yet to be created.
There are 16 Key Major Players including Pfizer, Prude Pharma L.P, Novartis, Janssen Pharma, Takeda, Sunovion, Tris Pharma, etc. Also, there are 14 companies which are classified as New Market Entrants and Emerging Companies.
In May 2019, FDA approved the Monarch eTNS System for ADHD treatment in children aged 7-12 yrs which will be commercialized by NeuroSigma, Inc.,
In June 2019, Researchers from Tehran University confirmed that saffron capsules offer the same effect as methylphenidate on ADHD.
In June 2019, Ironshore Pharmaceutical’s DELEXIS® (novel drug delivery system) based JORNAY PM TM (methylphenidate HCl) extended-release capsule was launched in the US.
In June 2019, Haifa-based InnoSphere’s patented medical “cap” provides promising results for ADHD treatment. The device is said to hit the market by 2022.
The Report Provides Key Insights on
- History of the ADHD Treatment Market, 2015 to 2017
- Forecast of the ADHD Treatment Market Growth till the year 2026
- The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the ADHD Treatment Market
- Analysis of potential growth segments which will drive the market
- Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
- Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Request for sample pages @ https://www.optimainsights.org/sample-request/142-attention-deficit-hyperactivity-disorder-market
Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Drug Type (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- Clonidine (Kapvay)
- Guanfacine (Intuniv)
- Atomoxetine (Strattera)
- Lisdexamfetamine dimesylate (Vyvanse)
- Dextroamphetamine (Dexedrine, ProCentra, Zenzedi)
- Methylphenidate (Concerta, Daytrana)
- Amphetamine (Adzenys XR ODT, Evekeo)
Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Age Group (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- Pediatric and neonates
Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Distribution Channel (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- Retail Pharmacies
- Hospital Pharmacies
- Specialty Clinics
Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- North America
Attention Deficit Hyperactivity Disorder (ADHD) Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)
- Eli Lilly and Company
- Pfizer Inc
- Novartis AG
- Takeda Pharmaceutical Company Ltd
- Tris Pharma
- Taisho Pharma
- NEOS Therapeutics Inc
- Noven Pharmaceuticals
- Prude Pharma L.P
Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/142-attention-deficit-hyperactivity-disorder-market
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)